AFC-HD AMS Life Science Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for AFC-HD AMS Life Science.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Personal Products earnings growth | 18.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
AFC-HD AMS Life Science (TSE:2927) Is Due To Pay A Dividend Of ¥15.00
Apr 17
Here's Why I Think AFC-HD AMS Life Science (TYO:2927) Might Deserve Your Attention Today
Apr 29These 4 Measures Indicate That AFC-HD AMS Life Science (TYO:2927) Is Using Debt Safely
Apr 14AFC-HD AMS Life Science Co., Ltd.'s (TYO:2927) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 09Is It Smart To Buy AFC-HD AMS Life Science Co., Ltd. (TYO:2927) Before It Goes Ex-Dividend?
Feb 20The Trends At AFC-HD AMS Life Science (TYO:2927) That You Should Know About
Feb 04Here's Why I Think AFC-HD AMS Life Science (TYO:2927) Is An Interesting Stock
Jan 17These 4 Measures Indicate That AFC-HD AMS Life Science (TYO:2927) Is Using Debt Reasonably Well
Dec 29AFC-HD AMS Life Science Co., Ltd. (TYO:2927) On An Uptrend: Could Fundamentals Be Driving The Stock?
Dec 02
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AFC-HD AMS Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 2/29/2024 | 27,677 | 1,329 | -2,706 | 204 | N/A |
| 11/30/2023 | 26,679 | 1,260 | N/A | N/A | N/A |
| 8/31/2023 | 25,579 | 1,102 | -1,074 | 865 | N/A |
| 5/31/2023 | 25,000 | 882 | N/A | N/A | N/A |
| 2/28/2023 | 24,253 | 842 | 440 | 1,576 | N/A |
| 11/30/2022 | 23,229 | 739 | N/A | N/A | N/A |
| 8/31/2022 | 22,997 | 735 | 535 | 1,492 | N/A |
| 5/31/2022 | 24,565 | 671 | N/A | N/A | N/A |
| 2/28/2022 | 24,406 | 1,068 | 399 | 1,180 | N/A |
| 11/30/2021 | 23,185 | 1,276 | N/A | N/A | N/A |
| 8/31/2021 | 22,368 | 1,495 | 2,091 | 2,582 | N/A |
| 5/31/2021 | 18,641 | 1,594 | N/A | N/A | N/A |
| 2/28/2021 | 17,077 | 1,058 | 2,035 | 2,477 | N/A |
| 11/30/2020 | 16,603 | 890 | N/A | N/A | N/A |
| 8/31/2020 | 15,819 | 676 | 918 | 1,299 | N/A |
| 5/31/2020 | 15,706 | 557 | N/A | N/A | N/A |
| 2/29/2020 | 15,806 | 633 | 957 | 1,424 | N/A |
| 11/30/2019 | 15,844 | 717 | N/A | N/A | N/A |
| 8/31/2019 | 16,252 | 783 | 585 | 1,131 | N/A |
| 5/31/2019 | 16,299 | 896 | N/A | N/A | N/A |
| 2/28/2019 | 16,410 | 900 | 572 | 989 | N/A |
| 11/30/2018 | 16,212 | 786 | N/A | N/A | N/A |
| 8/31/2018 | 15,795 | 736 | 672 | 1,221 | N/A |
| 5/31/2018 | 15,744 | 598 | N/A | N/A | N/A |
| 2/28/2018 | 15,534 | 575 | 153 | 1,209 | N/A |
| 11/30/2017 | 15,377 | 536 | N/A | N/A | N/A |
| 8/31/2017 | 15,141 | 465 | N/A | 525 | N/A |
| 5/31/2017 | 14,864 | 427 | N/A | N/A | N/A |
| 2/28/2017 | 14,544 | 378 | N/A | 235 | N/A |
| 11/30/2016 | 14,391 | 375 | N/A | N/A | N/A |
| 8/31/2016 | 14,631 | 489 | N/A | 854 | N/A |
| 5/31/2016 | 15,013 | 646 | N/A | N/A | N/A |
| 2/29/2016 | 15,054 | 730 | N/A | 771 | N/A |
| 11/30/2015 | 14,892 | 726 | N/A | N/A | N/A |
| 8/31/2015 | 14,415 | 605 | N/A | 856 | N/A |
| 5/31/2015 | 13,586 | 400 | N/A | N/A | N/A |
| 2/28/2015 | 13,618 | 292 | N/A | 1,164 | N/A |
| 11/30/2014 | 13,643 | 252 | N/A | N/A | N/A |
| 8/31/2014 | 13,727 | 282 | N/A | 892 | N/A |
| 5/31/2014 | 13,995 | 411 | N/A | N/A | N/A |
| 2/28/2014 | 13,975 | 536 | N/A | 1,033 | N/A |
| 11/30/2013 | 14,157 | 583 | N/A | N/A | N/A |
| 8/31/2013 | 14,366 | 572 | N/A | 1,576 | N/A |
| 5/31/2013 | 14,598 | 601 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2927's forecast earnings growth is above the savings rate (0.2%).
Earnings vs Market: Insufficient data to determine if 2927's earnings are forecast to grow faster than the JP market
High Growth Earnings: Insufficient data to determine if 2927's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2927's revenue is forecast to grow faster than the JP market.
High Growth Revenue: Insufficient data to determine if 2927's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2927's Return on Equity is forecast to be high in 3 years time